Equities

Capstone Therapeutics Corp

CAPS:QBB

Capstone Therapeutics Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.20
  • Today's Change0.00 / 0.00%
  • Shares traded1.00
  • 1 Year change-54.29%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 19:19 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Capstone Therapeutics Corp., formerly Capstone Holding Corp., operates, through its wholly owned subsidiary, TotalStone, LLC, which is a construction materials company. TotalStone, LLC distributes masonry stone products for residential and commercial construction in the Midwest and Northeast United States. The Company, through its subsidiary, Capstone Beta, LLC, owns an equity interest in Diamond Products, LLC, which is a sexual wellness products holding company. Diamond Products, LLC product portfolio includes adult toys, lingerie, games, lotions and creams that are sold globally in over 80 countries through 5,000 retailers, as well as e-commerce Websites.

  • Revenue in USD (TTM)0.00
  • Net income in USD-358.00k
  • Incorporated2008
  • Employees2.00
  • Location
    Capstone Therapeutics CorpSUITE 101, 1275 WEST WASHINGTON STREETTEMPE 85281United StatesUSA
  • Phone+1 (602) 286-5520
  • Fax+1 (302) 655-5049
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CNBX Pharmaceuticals Inc230.08k-1.21m284.67k2.00------1.24-0.0458-0.04580.0081-0.07890.6201----115,040.00-325.63-73.32---99.8014.96---525.10-3,970.88---1.34------111.900.3497------
Endonovo Therapeutics Inc255.72k-4.40m317.46k0.00------1.24-0.0652-0.06520.0003-0.0720.2256-------388.54-303.26----96.2174.38-1,722.26-5,956.27---1.38----85.15---495.02------
Neximmune Inc0.00-20.62m338.73k6.00--0.4864-----18.59-18.590.000.660.00----0.00-140.56-115.07-224.94-165.07------------0.00------48.25---44.65--
GlobeStar Therapeutics Corp0.00-1.98m348.88k-----------0.0023-0.00230.00-0.00150.00-------38,103.72-4,657.88-------7,790.20---2,834,410.00---21.00---------31.01------
Yield10 Bioscience Inc750.00k-12.70m363.66k29.00------0.4849-135.92-135.921.95-9.710.1697----25,862.07-287.44-91.26---108.09-----1,693.60-2,279.74---------86.67-35.94-6.55--1.84--
LadRx Corp0.00-2.78m364.98k2.00---------5.61-5.610.00-3.540.00----0.00-177.00-58.97---78.44--------------------106.96------
Regenerative Medical Technology Grop Inc2.87m-10.15m394.98k1.00------0.1375-0.8144-0.81440.2303-2.070.5424--76.15---191.67-192.08----68.9560.24-353.35-821.490.0257-0.0755----57.49116.97-76.03--149.35--
Capstone Therapeutics Corp0.00-358.00k504.35k2.00---------6.58-38.120.00-60.700.00-------113.46141.94-199.60173.06-----------2.92--------52.46------
Novelstem International Corp12.00k-3.02m520.38k15.00------43.37-0.0644-0.06440.0003-0.10650.0108--3.20---106.25-----------9,816.08-----4.90----0.00---446.84------
NovAccess Global Inc0.00-1.89m594.31k1.00---------0.0999-0.09990.00-0.11990.00----0.00-840.23-2,185.89---------------2.94---------177.93------
Data as of Nov 22 2024. Currency figures normalised to Capstone Therapeutics Corp's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.